DAFTAR PUSTAKA

1. McLeod S, Lansavichene A, Cheskes S. Remote ischemic perconditioning to reduce reperfusion injury during acute ST-segment-elevation myocardial infarction: a systematic review and meta-analysis. *J Am Hear Assoc*. 2017;6-20.
2. Hausenloy DJ, Yellon DM. Myocardial ischemic conditioning: Pathogenesis. 2018;1–16.
3. Gao S, Zhan L, Yang Z, Shi R, LI H, Xia Z, et al. Remote Limb Ischaemic Postconditioning Protects Against Myocardial Ischaemia / Reperfusion Injury in Mice : Activation of JAK / STAT3-Mediated Nrf2-Antioxidant Signalling. *Cell Physiol Biochem*. 2017;43:1140–1151.
4. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. *Circ Res*. 2008;103:1204–1219.
5. Lim H. Mekanisme Perbaikan dan Regenerasi Jantung. In: Revolusi Sel Punca Kedokteran Kardiovaskuler Volume 1. PT. Sofmedia; 2010. p. 71–80.
6. Ghadge SK, Mühlstedt S, Özcelik C, Bader M. SDF-1α as a therapeutic stem cell homing factor in myocardial infarction. *Pharmacol Ther*. 2011;129:97–108.
7. Falk E, Bentson J. New and Emerging Insights Into the Pathobiology of Acute Myocardial Infarction. In: Myocardial Infarction A Companion to Braunwald's Heart Disease. Missouri: Elsevier; 2017. p. 22–33.
8. Irmalita, Juzar DA, Andrianto, Setianto BY, Tobing DP, Firman D, Firdaus I. Pedoman tatalaksana sindrom koroner akut. 2015. p. 1–88.
9. Topol E, Werf F. Acute myocardial infarction: early diagnosis and management. In: Textbook of Cardiovascular Medicine. Philadelphia: Lippincott Williams and Wilkins; 2007. p. 280–281.
10. Scirica B, Morrow D. ST-elevation myocardial infarction: pathology, pathophysiology, and clinical features. In: Braunwald's Heart Disease. A Textbook of Cardiovascular Medicine. Philadeplhia: Elsevier; 2015. p. 1072–1088.
11. Wang X, Wang J, Tu T, Iyan Z, Mungun D, Yang Z, et al. Remote Ischemic Postconditioning Protects against Myocardial Ischemia-Reperfusion Injury by Inhibition of the RAGE-HMGB1 Pathway. *Biomed Res Int*. 2018;2018:1–9.
12. Frank A, Bonney M, Bonney S, Weitzel L, Koeppen M, Eckle T. Myocardial ischemia reperfusion injury: From basic science to clinical bedside. *Semin Cardiothorac Vasc Anesth*. 2012;16:123–132.
13. Gross GJ, Auchampach JA. Reperfusion injury: Does it exist? *J Mol Cell Cardiol*. 2007;42:12–18.
14. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell Biology of Ischemia/Reperfusion Injury. 2012.
15. Cao B, Wang H, Zhang C, Xia M, Yang X. Remote ischemic postconditioning (RIPC) of the upper arm results in protection from cardiac ischemia-reperfusion injury following primary percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction (STEMI). *Med Sci Monit*. 2018;24:1017–1026.
16. Cheung MMH, Kharbanda RK, Konstantinov IE, Shimizu M, Frndova H, Li J, et al.. Randomized Controlled Trial of the Effects of Remote Ischemic Preconditioning on Children Undergoing Cardiac Surgery. First Clinical Application in Humans. *J Am Coll Cardiol*. 2006;47:2277–2282.
17. White SK, Frohlich GM, Sado DM, Maestrini V, Fontana M, Treibel TA, et al. Remote ischemic conditioning reduces myocardial infarct size and edema in patients with ST-segment elevation myocardial infarction. *JACC Cardiovasc Interv*.

2015;8:178–188.
18. Kaur S, Jaggi AS, Singh N. Molecular aspects of ischaemic postconditioning. *Fundam Clin Pharmacol*. 2009;23:521–536.
19. Vinten-Johansen J, Zhao ZQ, Jiang R, Zatta AJ. Myocardial protection in reperfusion with postconditioning. *Expert Rev Cardiovasc Ther*. 2005;3:1035–1045.
20. Rossello X, Yellon DM. The RISK pathway and beyond. *Basic Res Cardiol*. 2018;113:1–5.
21. Takahashi M. Role of the SDF-1/CXCR4 system in myocardial infarction. *Circ J*. 2010;74:418–423.
22. Janssens R, Struyf S, Proost P. The unique structural and functional features of CXCL12. *Cell Mol Immunol*. 2018;15:299–311.
23. Miller MC, Mayo KH. Chemokines from a structural perspective. *Int J Mol Sci*. 2017;18:1–16.
24. Ceradini D, Kulkarni A, Callghan M, Tepper O, Kleinman M, Bastidas M. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. *Nat Med*. 2004;10:858.
25. Bromage DI, Davidson SM, Yellon DM. Stromal derived factor 1α A chemokine that delivers a two pronged. *Pharmacol Ther*. 2014;3:3015–3015.
26. Lau TT, Wang DA. Stromal cell-derived factor-1 (SDF-1): Homing factor for engineered regenerative medicine. *Expert Opin Biol Ther*. 2011;11:189–197.
27. Pauline D. Synthesis and studies of new optimised chelating agents for targeting chemokine receptor CXCR4. 2013;1-156.
28. Yin Y, Zhao X, Fang Y, Yu S, Zhao J, Song M, et al. SDF-1α involved in mobilization and recruitment of endothelial progenitor cells after arterial injury in mice. Cardiovasc. Pathol. 2010;19:218–227.
29. Luft FC. The promise of stromal cell-derived factor-1 in novel heart disease treatments. *J Mol Med*. 2017;95:821–823.
30. Tennant D, Howell NJ. The role of HIFs in ischemia-reperfusion injury. *Hypoxia*. 2014;107.
31. Chang LT, Yuen CM, Sun CK, Wu CJ, Sheu JJ, Chua S, et al. Role of stromal cell-derived factor-1α, level and value of circulating interleukin-10 and endothelial progenitor cells in patients with acute myocardial infarction undergoing primary coronary angioplasty. Circ. J. 2009;73:1097–1104.
32. Davidson SM, Selvaraj P, He D, Boi-Doku C, Yellon RL, Vicencio JM, et al. Remote ischaemic preconditioning involves signalling through the SDF-1α/CXCR4 signalling axis. *Basic Res Cardiol*. 2013;108.
33. Firman D. Tinjauan Pustaka Intervensi Koroner Perkutan Primer. *J Kardiol Indones*. 2010;31:112–117.
34. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J*. 2019;40:87–165.
35. F. Piepoli M. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. *Int J Behav Med*. 2017;24:321–419.
36. Kang MJ, Oh YM, Lee JC, Kim DG, Park MJ, Lee MG, et al. Lung Matrix Metalloproteinase-9 Correlates with Cigarette Smoking and Obstruction of Airflow. *J Korean Med Sci*. 2003;18:821–827.
37. Soelistijo S, Novida H, Rudijanto A, Suastika K, Manaf A. Definisi, pathogenesis, klasifikasi diabetes mellitus. In: Konsensus pengelolaan dan pencegahan diabetes

mellitus tipe 2 di Indonesia 2015. Jakarta. 2015. p. 6–11.
38. Zimarino M, Calafiore AM, De Caterina R. Complete myocardial revascularization: Between myth and reality. *Eur Heart J*. 2005;26:1824–1830.
39. Uematsu M, Yoshizaki T, Shimizu T, Obata JE, Nakamura T, Fujioka D, et al. Sustained myocardial production of stromal cell-derived factor-1α was associated with left ventricular adverse remodeling in patients with myocardial infarction. *Am J Physiol - Hear Circ Physiol*. 2015;309:H1764–H1771.
40. Kern MJ. Angiography for percutaneous coronary intervention. In: The Interventional Cardiac Catheterization Handbook 3rd Edition. Philadeplphia: Elsevier Saunders; 2013. p. 83–107.
41. Freisinger E, Sehner S, Malyar NM, Suling A, Reinecke H, Wegscheider K. Nationwide Routine-Data Analysis of Sex Differences in Outcome of Acute Myocardial Infarction. 2018;1013–1021.
42. Barua RS, Ambrose JA. Mechanisms of coronary thrombosis in cigarette smoke exposure. *Arterioscler Thromb Vasc Biol*. 2013;33:1460–1467.
43. Messner B, Bernhard D. Smoking and cardiovascular disease: Mechanisms of endothelial dysfunction and early atherogenesis. *Arterioscler Thromb Vasc Biol*. 2014;34:509–515.
44. Konstantinou K, Tsioufis C. Hypertension and patients with acute coronary syndrome : Putting blood pressure levels into perspective. 2019;1135–1143.
45. Heusch G, Botker H, Przyklenk K, Redington A, Yellon D. Remote Ischemic Conditioning. *J Am Coll Cardiol*. 2015;65:177–95.
46. Tang YL, Zhu W, Cheng M, Chen L, Zhang J, Sun T, et al. Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. *Circ Res*. 2009;104:1209–1216.
47. Kamota T, Li TS, Morikage N, Murakami M, Ohshima M, Kubo M, et al. Ischemic Pre-Conditioning Enhances the Mobilization and Recruitment of Bone Marrow Stem Cells to Protect Against Ischemia/Reperfusion Injury in the Late Phase. *J Am Coll Cardiol*. 2009;53:1814–1822.
48. Kim JS, Jang Y, Kim JH, Park YH, Hwang SA, Kim J, et al. Cardioprotective effect of the sdf-1α/cxcr4 axis in ischemic postconditioning in isolated rat hearts. *Korean Circ J*. 2017;47:949–959.
49. Hu X, Dai S, Wu WJ, Tan W, Zhu X, Mu J, et al. Stromal cell-derived factor-1α confers protection against myocardial ischemia/reperfusion injury: Role of the cardiac stromal cell-derived factor-1α-CXCR4 axis. *Circulation*. 2007;116:654–663.
50. Bromage DI, Teferner S, He Z, Ziff OJ, Yellon DM, Davidson SM. Stromal cell derived factor 1α signals via the endothelium to protect the reperfusion injury.pdf. *J Mol Cell Cardiol*. 2019;128:187–197.
51. Segers VFM, Tokunou T, Higgins LJ, MacGillivray C, Gannon J, Lee RT. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. *Circulation*. 2007;116:1683–1692.
52. Lim SY, Yellon DM, Hausenloy DJ. The neural and humoral pathways in remote limb ischemic preconditioning. *Basic Res Cardiol*. 2010;105:651–655.